Ayala Pharmaceuticals Inc (ADXS)

[BarrellofHay]

Ok, I am beginning to understand. Survival rates are highly dependent on stages:

https://www.cancer.org/cancer/anal-cancer/detection-diagnosis-staging/survival-rates.html

The Cetuximab study was on stage II patients who have a really good chance of surviving

ADXS dosed probably mainly stage IV patients WHO ALSO failed prior therapies.

Therefore a 28% PFS seems pretty good but still not comparable because there is NOTHING TO COMPARE.

Why are they using the sickest patients?

I am changing my tune again. My apologies, I have been up/down bipolar posting because I shoot from the hip too much (in real life too:) )

I really think that anal was canceled because of (IMO):

1) the cost
2) focus on cervical because it is further along
3) focus on cervical because it affects far far more people than ANAL does. This is key, get it to work with the worlds #2 cancer killer and then go after the smaller markets (although I hate to think of peoples lives as "markets" and really hope they get a sponsor/buyer for anal cancer and all other HPV related cancers)